newsfilter
← Latest News
GlobeNewswire·

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into the clinic, continuing leadership in the Hippo pathway therapeutic landscape Expanded IK-175